Objective-Resistance to obesity is observed in rodents and humans treated with Rapamycin (Rap) or Nebivolol (Neb). Since cardiac miR-208a promotes obesity, we tested whether the modes of actions of Rap and Neb involve inhibition of miR-208a.
INTRODUCTION
The worldwide epidemic of obesity now affects more than 2 billion people, costing the world's economy two trillion dollars per year ( 1 ) . Since obesity is a risk factor for cardiovascular disease and diabetes ( 2 -4 ) , it is critical to examine the causal mechanisms and interrelationships of these diseases. Elegant studies have established the significance of cardiac microRNA miR-208a in cardiac development and pathology ( 5 -8 ) . Encoded by intron 27 of the cardiac specific α-myosin heavy chain (MHC) gene Myh6, miR-208a is a member of the miR-208 family of miRNAs. Up-regulation of miR-208a in response to stress suppresses transcriptional repression of β-cardiac muscle myosin heavy chain gene (Myh7) and promotes switching of expression from αMHC to βMHC, resulting in myocardial contractile dysfunction. A unique trait of miR-208a is that pharmacological inhibition of miR-208a by anti-miR-208a confers resistance to obesity ( 9 ) . This effect of miR-208a is attributed to its ability to inhibit Mediator Complex 13 (MED13) synthesis, since overexpression of cardiac specific MED13 confers resistance to obesity and controls systemic energy homeostasis ( 9 ) . MED13 is also known as thyroid hormone-associated protein 1 (THRAP1) and is implicated in the anti-obesity effects of thyroid hormone signaling ( 9 ) .
Although β-Adrenergic receptor blockers are effective in treating cardiovascular diseases ( 10 -12 ) some cause weight gain ( 13 ) . However, reports from our lab and others indicate that treatment with the 3 rd generation β-blocker nebivolol (Neb) inhibits weight gain ( 14 , 15 ) . The exact mechanisms by which Neb inhibits weight gain are unclear. It is known that the serine/threonine kinase mammalian target of rapamycin complex 1 (mTORC1) integrates inputs from nutritional stimuli with the cellular growth machinery, and activation of mTORC1 is central to the onset of obesity ( 4 , 16 , 17 ) . We have reported that Neb attenuates activation of mTORC1 in heart tissues of Zucker obese (ZO) rats, an animal model for hyperinsulinemia, leptin resistance, and obesity ( 14 ) . Therefore, inhibition of mTORC1 could be the mechanism by which Neb suppresses body weight gain in ZO rats. It is not known whether suppression of cardiac miR-208a, which can also induce resistance to weight gain, is involved in Neb's mode of action.
Chronic Rapamycin (Rap) treatment also inhibits weight-gain in rodent models of obesity ( 18 -20 ) . Originally identified as an anti-fungal compound, Rap is now widely used as an immunosuppressant and anticancer therapeutic ( 21 , 22 ) . Rap is the canonical inhibitor of mTOR (mammalian target of rapamycin). Though the modes of action of Rap and Neb are different, both drugs confer resistance to obesity and attenuate mTORC1. We hypothesized that signaling by both Rap and Neb converges in a common mechanism that involves mTORC1 and miR-208a. To test this idea, we assessed the effects of angiotensin II (Ang II), Rap and Neb on mTORC1 activation and miR-208a expression using mouse cardiomyocyte HL-1 cells ( 23 ) . We also tested whether chronic Rap treatment of leptin resistant and hyperphagic Zucker obese rats (ZO) causes resistance to weight gain that is correlated with suppression of cardiac miR-208a and increased expression of cardiac MED13. Data presented here shows for the first time that Rap and Neb inhibit AT1R-induced activation of mTORC1 and also inhibit upregulation of miR-208a expression. Moreover, we report that chronic Rap treatment conferred resistance to weight gain in leptin resistant ZO rats, attenuated cardiac miR-208a expression and increased the obesity suppressor cardiac MED13.
METHODS

Cell culture and treatments
Mouse atrial cardiomyocyte HL-1 cells were a gift from Dr. William Claycomb at Louisiana State University Medical Center and were cultured as described previously ( 18 , 23 ) . Nebivolol was a gift from Forest Laboratories Inc. (New York) and rapamycin was purchased from Cell Signaling Technology (Boston, MA). Human Ang II was purchased from Sigma-Aldrich. Losartan (AT1R inhibitor), PD123319 (AT2R inhibitor), apocynin (NADPH Oxidase inhibitor) and U73122 (Phospholipase C inhibitor) were purchased from TOCRIS Biosciences.
Rapamycin treatment of rats, body composition, food intake and tissue collection
All animal procedures used in this study were approved by the Harry S. Truman Veterans Memorial Hospital (HSTVMH) Subcommittee for Animal Safety and University of Missouri IACUC before commencing. All animals were cared for in accordance with the Guidelines for the Care and Use of Laboratory Animals (National Institutes of Health publication 85-23). Zucker obese (fa/fa) (ZO) and lean (ZL) rats (Charles River Laboratories) were used in this study. Rats were maintained on ad libitum food and water and housed singly at the HSTVMH animal housing facility under standard laboratory conditions (room temperature: 21-22°C; light and dark cycles: 12h). Food intake was monitored by placing a pre-weighed amount of food in the cage and determining the weight of leftover food after 24 hrs. At 8-weeks of age, rapamycin pellets designed to deliver Rap at a concentration of 750µg/kg/day for 21 days (from Innovative Research of America, Inc, Sarasota, FL) or placebo pellets were placed surgically under the skin behind the shoulder blades under brief isoflurane anesthesia and this procedure was repeated 3 times to achieve a 12-week treatment. Body composition was determined using the EchoMRI 4in1/1100 as described previously ( 18 ) . Hearts were harvested at time of sacrifice as described before ( 18 ) , flash frozen in liquid nitrogen, and stored at -80°C for future use.
RNA isolation, quantitative RT-PCR, and Immunoblotting
The mirVana miRNA isolation kit (Ambion) was used for isolation of miRNA and mRNA. Quantitative RT-PCR (qRT-PCR) was performed as described previously ( 18 ) . Taqman microRNA assay primers for miR-208a and small nuclear RNA (snRNA) (Taqman microRNA Assays) and rat MED13 and 18S RNA primers (Gene Expression Assays) were from Applied Biosystems. Experiments were performed in triplicate for each biological sample. Relative quantification (RQ) values were obtained by determining ΔCt values followed by determining ΔΔCt values and then RQ values via the equation 2 −ΔΔCt .
Cell lysates of HL-1 cells were prepared and Western blotting was performed as described previously ( 18 ) . Experiments were performed in at least in triplicate for each biological sample. All antibodies except anti-β-MHC antibody were from Cell Signaling Technology Inc. (Boston, MA). The mouse monoclonal anti-β-MHC antibody which is highly specific for Myh7 product was from Sigma, (St. Louis, MO; Mouse Monoclonal Anti-myosin (skeletal, slow) antibody, M8421). The blots were blocked with 5% bovine serum albumin (BSA) in Trisbuffered saline-Tween 20 (TBST) for one hr. After blocking, PVDF membranes were probed with primary antibodies (1:1000 dilution of each antibody) for mTOR, phospho-mTOR (Ser 2448 ), p70S6K, phospho-p70S6K (Thr 389 ), RPS6, phospho-RPS6 (Ser 235/236 ), Jak2, phospho-Jak2 (Tyr 1007/1008 ), STAT1, phospho-STAT1(Tyr 701 ), or β-MHC, in 5% BSA in TBST overnight and washed with TBST prior to the addition of horseradish peroxidase-conjugated secondary antibody (1:20,000). After 1 hr incubation at room temperature with secondary antibodies and washing with TBST, chemiluminescent substrate (Supersignal West Femto Maximum Sensitivity Substrate kit; Thermo Scientific) was used to visualize antibody binding. Images were captured using a Bio-Rad ChemiDoc XRS image-analysis system. Quantitation of phosphorylated protein band density normalized to the density of total protein or protein band density normalized to the density of β-actin band for each sample, was performed using Quantity One software (Bio-Rad Laboratories Inc. Berkeley, Ca). Data are reported as the normalized protein band density in arbitrary units.
Immunofluorescence
Immunofluorescence was used to determine the changes in the expression of β-MHC in HL-1 cells in response to different treatments. Briefly, HL-1 cells were grown on cover slips as described previously ( 18 ) . All treatments were performed in triplicates. After treatments with Ang II (100nM:12hr) or Neb (1µM: 12hr) coverslips were washed with HEPES (Sigma), fixed with 4% paraformaldehyde for 15 min at room temperature, permeabilized with 0.5% Triton-X-100, washed with HEPES-T (1mL Tween-20/L), and blocked with 1% bovine serum albumin (BSA) (Jackson ImmunoResearch), 10% goat serum (Sigma) and 0.1% Tween 20 (Fisher Scientific). Cells were incubated with anti-β-MHC antibody (Sigma) (1:100 dilution) overnight at 4°C and repeatedly washed with HEPES. The coverslips were then incubated with Alexa Fluor 488 goat anti-rabbit (Invitrogen Inc.) (1:200 dilution) for 1 hr at room temperature. Coverslips were washed with HEPES and mounted with Fluoroshield with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) and visualized using a Leica DMI 4000B inverted confocal microscope using Leica Application Suite software. Imaging was done at 60x magnification using oil immersion.
Radioligand binding studies
HL-1 cardiomyocytes were incubated in serum-free Claycomb medium with or without Neb (1µM) or Losartan (1µM) or PD123319 (5µM) for 12 hrs. Each treatment was performed at least in triplicate. Cells were collected by trypsinization (0.05% Trypsin), and resuspended in ice-cold Claycomb medium. The number of cells per sample was determined using Millipore Scepter and cell numbers in all samples were adjusted to have 10 6 cells/mL. Next, 200µl of cell suspension for each treatment group (untreated, or Neb-, losartan-, and PD123319-treated) was transferred to microfuge tubes. Cells were collected by centrifugation, and re-suspended in 190 µl of ice-cold pre-incubation medium ( 24 ) with or without Ang II (1µM). Cells that received 12hr treatment with Neb or Losartan were resuspended in pre-incubation medium containing Neb (1µM) or losartan (1µM). In addition, different aliquots of untreated cells were treated with pre-incubation medium containing either Neb (1µM) or losartan (1µM) or neither drugs to determine whether short-term pretreatment with Neb or losartan prior to the ligand-binding procedure had any effect on 125 I-Ang II binding to HL-1 cells.
The 125 I-Ang II was prepared using the chloramine T procedure ( 25 ) . Monoradioiodinated Ang II was purified by HPLC as described previously ( 26 ) . After a 30 min pre-incubation, 10µl of pre-incubation medium containing 125 I-Ang II was added to achieve a final concentration of 1nM. After a2 hour incubation on ice, cells were collected by centrifugation, washed three times with ice-cold PBS and the radioactivity in the pellet was monitored using Perkin Elmer-Wallac Wizard 1480 gamma counter. Specific binding for the cells from each group was determined by subtracting the counts obtained from cell pellets that were incubated in the pre-incubation medium containing non-radioactive Ang II (1µM). The specific binding obtained for the untreated sample under these conditions was taken as 100%. The % specific binding of 125 I-Ang II to HL-1 cells after each treatment in comparison with the untreated sample was calculated.
Statistics
The SPSS 20 software package was used for statistical analysis. Results were expressed as mean ± SEM (standard error of mean). Differences among groups were tested by using OneWay ANOVA followed by Tukey's test or Student's t-test, as appropriate, and two-tailed p values are reported. A p-value of ≤ 0.05 was considered statistically significant.
RESULTS
Effects of Angiotensin II, Rapamycin and Nebivolol on miR-208a expression in HL-1 cardiomyocytes
We investigated whether Ang II would increase, and Neb and Rap would suppress Ang IIinduced miR-208a expression in HL-1 cardiomyocytes. Ang II treatment (100nM: 12hr) of serum starved HL-1 cardiomyocytes increased miR-208a expression by ~5 fold (Fig. 1A) . Pretreatment with AT1R blocker losartan (1µM) suppressed this effect, however, pretreatment with the NADPH oxidase inhibitor apocynin (0.5mM) and phospholipase C (PLC) inhibitor U73122 (10µM) did not significantly attenuate the Ang II-induced increase in miR-208a expression (Fig. 1A) . Importantly, Rap (10nM) and Neb (1µM) suppressed the Ang II-induced increase in miR-208a expression (Fig. 1B) . These observations suggest that the Ang II induced increase in miR-208a expression is mediated via a mechanism regulated by Rap and Neb. Since Rap inhibits mTORC1, we tested whether Ang II activated mTORC1, and whether Rap and Neb suppressed this effect in HL-1 cells. We examined phosphorylation (p) status of Ser 2448 of mTOR, Thr 389 of p70 S6 kinase (S6K1), the substrate of mTORC1, and Ser235/236 of Ribosomal Protein S6 (RPS6), the substrate of S6K1. Ang II (100nM:12hr) increased stimulatory phosphorylation of mTOR (pSer 2448 ), S6K1 (pThr 389 ) and RPS6 (p Ser 235/236 ), and this effect was suppressed by pretreatment (Figs 1C-E) . Thus, Ang II activates mTORC1 via AT1R, while both Rap and Neb suppress this effect.
Increased miR-208a is reported to increase β-myosin heavy chain (βMHC) protein levels ( 5 -8 ) . To further confirm that Ang II and Neb treatments have opposing effects on βMHC expression, we treated HL-1 cardiomyocytes with Ang II (100nM:12hr), Neb (1µM:12hrs), and Ang II plus Neb (100 nM and 1 µM, respectively:12hr). Western blotting analysis showed that Ang II increased the expression of βMHC in HL-1 cells and Neb suppressed the Ang II-induced increase (Fig. 2A) . Immunofluorescence analysis further confirmed Neb's inhibitory effect on βMHC expression (Fig. 2B) . Western blotting analysis also showed that Rap (10nM:12hrs) suppressed the Ang II-induced increase in βMHC expression (Fig. 2C) 
Mode of action of Neb in miR-208a regulation
Since Neb suppressed Ang II-induced increases in miR-208a we investigated which Nebmediated signaling mechanism(s) contributed to this effect. In addition to being a β1-AR blocker, Neb is known to act as an agonist of β3-AR and also to activate endothelial nitric oxide synthase (eNOS) and AMP kinase ( 27 -31 ) . Therefore, it is conceivable that Neb may inhibit miR-208a expression via mechanisms independent of Ang II-induced AT1R activation, such as activation of β3-AR, NOS, or AMP kinase. However, treatment with β3-AR blocker SR59230 (10µM), AMP kinase inhibitor Compound C (10µM) or NOS inhibitor L-NG-Nitroarginine methyl ester (L-NAME) (10µM) failed to reverse the Neb-mediated suppression of Ang II-induced increase in miR-208a expression in HL-1 cardiomyocytes (Fig. 3A) . These observations suggest that Neb inhibits Ang II-induced increases in miR-208a by a mechanism that does not involve Neb induced activation of β3-AR-AMKeNOS pathway.
To further understand the mechanism of Neb-mediated suppression of Ang II-induced miR-208a expression, we investigated whether Neb suppressed bioavailable AT1R levels in HL-1 cardiomyocytes that bind 125 I-Ang II. When HL-1 cells were pre-treated with either Neb (1µM: 12hrs) or losartan (1µM:12hrs) before a ligand binding experiment was performed, both treatments caused equivalent reductions in 125 I-Ang II binding to HL-1 cells ( Figure 3B ). However, when cells were not pre-treated with Neb or losartan overnight and these drugs were added only 30 minutes prior to the addition 125 I-Ang II for the radioligand binding assay, Neb did not suppress 125 I-Ang II binding, whereas losartan did. These results suggest that losartan competitively inhibited 125 I-Ang II binding because it inhibited 125 I-Ang II binding after both preincubation time intervals, but that Neb did not compete for 125 I-Ang II binding to HL-1 cells because it did not inhibit 125 I-Ang II binding when added 30 minutes before the binding assay. Therefore, Neb reduced 125 I-Ang II binding by decreasing bioavailable AT1 receptors.
Effect of Rapamycin treatment on weight gain, fat, lean muscle, and expression levels of cardiac miR-208a and MED13
To determine whether Rap-mediated suppression of cardiac miR-208a occurs in an obese rodent model, we investigated the effect of chronic Rap treatment (750µg/kg/day delivered by subcutaneous implantation of Rap pellets) for 12 weeks on ZO rats. ZL rats were used as healthy lean controls and ZL and ZO rats receiving placebo pellets served as controls to distinguish the specific effects of Rap treatment on both ZL and ZO rats. Body weights of ZO rats were significantly different from that of ZL rats (Fig. 4A) . ZO rats began to exhibit a reduction in body weight gain after two weeks of Rap treatment and their body weight was statistically significantly less than untreated ZO rats 10-12 weeks. (Fig. 4A) . Rap treatment did not significantly affect body weight in ZL rats (Fig. 4A) . Weight loss in Rap treated ZO rats was not due to a reduction in food intake (Fig. 4B) . EchoMRI analysis showed that Rap treatment significantly lowered fat content in ZO rats (Fig. 4C) and increased their lean muscle mass (Fig. 4D) . Rap treatment did not significantly change the fat content or lean muscle mass of ZL rats.
Since cardiac miR-208a is associated with obesity we determined expression levels of cardiac miR-208a in ZO and ZL rats at the age of 12 weeks and 20 weeks (Fig. 5A) . Quantitative RT-PCR showed that ZO rats had significantly higher levels of cardiac miR-208a than ZL rats at the age of 12-and 20-weeks (Fig.5A ). Next we tested whether Rap treatment could suppress miR-208a expression. As shown in Fig. 5B , Rap treatment suppressed cardiac miR-208a in ZO rats. Therefore, a possible mechanism by which Rap confers resistance to obesity is via suppression of cardiac miR-208a. Previous studies have shown that transgenic overexpression of cardiac MED13 confers resistance to obesity ( 9 ) . Indeed, Quantitative RT-PCR analysis showed that Rap treatment increased cardiac MED13 mRNA expression levels in ZO rats (Fig. 5C ). This is the first report showing concurrent Rap-induced reduction of cardiac miR-208a, increase of cardiac MED13 and reduction of weight gain in an animal model of obesity.
DISCUSSION
MicroRNA miR-208a serves as a link between cardiac pathology and obesity since mice treated with anti-miR-208a do not gain weight in response to DIO ( 9 ) . Given the role of miR-208a in the induction of obesity, it is reasonable to hypothesize that drugs that confer resistance to weight gain in rodent models that are hyperphagic due to deficient signaling of the satiety hormone leptin, may do so by suppressing cardiac miR-208a expression. The modes of action of Rap and Neb differ, Rap directly blocks mTORC1 whereas Neb binds β1-AR and does not directly interact with mTORC1 ( 15 -; 17 , 28 , 29 ) . However, both Neb and Rap induce weight loss in rodent models and humans ( 14 , 15 , 19 , 20 ) . Rap-induced inhibition of weight gain is attributed to its ability to inhibit the nutrient sensor kinase mTORC1 signaling. Neb is an interesting 3 rd generation β1-AR blocker that has pleotropic effects including activation of β3-AR and subsequent activation of AMP kinase that may lead to activation of eNOS (Fig. 6) . Moreover, Neb may also function as a GRK/β-arrestin biased agonist of β1-AR ( 32 ). We previously observed that Neb suppresses mTORC1 in ZO rat heart ( 14 ) however the pathway by which this occurs is still unknown.
Our observation that Neb and Rap suppress mTORC1 activation and miR-208a expression induced by Ang II in HL-1 cardiomyocytes suggests that both drugs use a common mechanism as part of their mode of action that involves mTORC1 and its ability to promote miR-208a formation. Rap is known to suppress stimulatory phosphorylation of Ser 2448 of mTOR ( 33 ) . Data presented here shows that Neb also suppresses stimulatory phosphorylation of Ser 2448 of mTOR. Therefore, signaling activated by Rap and Neb in cardiomyocytes converge at inhibition of stimulatory phosphorylation of Ser 2448 of mTOR and subsequent down-stream signaling (stimulatory phosphorylation of S6K1 at Thr 389 and RPS6 at Ser 235/236 ). We found that losartan, an AT1R blocker, could inhibit Ang II-induced mTOR phosphorylation and up-regulation of miR-208a expression whereas PD123319, an AT2R antagonist, did not inhibit mTOR phosphorylation and down-stream signaling. Interestingly, both Rap and Neb reduced miR-208a RNA expression more than losartan. This suggests that AT 1 receptor signaling is not the sole activator of mTOR in the HL-1 cells. Since mTORC1 inhibition decreases miR-208a formation, it is likely that AT1R-mTORC1 signaling regulates miR-208a (Fig. 6) . Antagonism of the β3-AR, inhibition of AMP kinase and NOS inhibition did not reverse Neb-mediated suppression of the Ang IIinduced increase in miR-208a in HL-1 cells affirming the lack of β3-AR involvement in Neb's effect on inhibition of Ang II-induced miR-208a expression. Interestingly, overnight treatment with Neb suppressed 125 I-Ang II binding to HL-1 cells. However, a 30-min pretreatment with Neb did not suppress 125 I-Ang II binding to HL-1 cells whereas losartan did. These observations suggest that Neb does not directly compete with 125 I-Ang II for binding sites; rather, the prolonged treatment with Neb substantially reduces bioavailable AT1R levels. Whether this involves inhibition of translation or transcription of the AT1R gene, or an impairment of trafficking of the AT1R to the membrane remains to be determined.
Importantly, results presented here show for the first time that in the ZO rat model for obesity, that Rap, an inhibitor of cardiac miR-208a increases cardiac MED13 levels, and confers resistance to obesity without reducing food intake. Previous studies have shown that inhibition of cardiac miR-208a by pharmacological intervention with anti-miR-208a oligonucleotide can confer resistance to obesity ( 9 ) . Our observation that the cardiac mTORC1-miR-208a-MED13 signaling axis that modulates obesity can be regulated by the widely used drugs, Neb and Rap, expands the potential clinical utility of these drugs. However, given the role of mTORC1 and miR-208a in cardiomyocyte development and cardiac stress response, any approach to suppress this signaling axis must be taken with great caution ( 18 , 34 -37 ) .
What is already known about this subject?
• Treatment with Rapamycin and Nebivolol attenuates weight gain in humans and rodents.
• Rapamycin and Nebivolol have different modes of action since Rapamycin inhibits mTOR Complex 1 formation and Nebivolol is a 3 rd generation β1-Adrenergic receptor blocker.
• Cardiac miR-208a-MED13 axis regulates systemic energy homeostasis and obesity.
What does this study add?
• Modes of action of Rapamycin and Nebivolol converge in suppressing Angiotensin II-induced and AT1Rmediated increase in miR-208a expression in mouse atrial cardiomyocyte HL-1 cells.
• In leptin resistant Zucker obese rats, a 12-week Rapamycin treatment suppresses weight gain without reducing food intake, attenuates the expression of the obesity inducer cardiac miR-208a, and increases the expression of cardiac MED-13, a promoter of systemic energy homeostasis.
• Rapamycin-mediated regulation of the cardiac miR-208a-MED13 axis is a new mechanism that may explain Rapamycin-mediated suppression of weight gain which is a clinically important phenomenon. Arrow marks when Rap treatment was started (8 weeks of age). N=6 animals for all groups until 17 th week and N=5 animals for Rap treated ZO for 19 th and 20 th week. One Rap treated ZO rat died of cardiac arrest in the 18 th week. Body weight, food intake, fat content and lean muscle mass of ZO rat was significantly different from Rap treated or untreated ZL rats at all data points (p < 0.05). *p < 0.05 for untreated versus Rap treated ZO rats. qRT-PCR data that shows ZO rat hearts expressed higher levels of miR-208a at the age of 12-weeks and 20-weeks compared to age-matched ZL rats (A); Rap treatment suppressed miR-208a expression in ZO rat heart (B); and Rap treatment increased MED13 expression in ZO rat heart (C). *p < 0.05 for ZL versus ZO and for untreated versus Rap treated ZO rats. Ang II acting through the AT1R activates the mTORC1-miR-208a signaling axis. Rap inhibits mTORC1 and thereby decreases miR-208a expression. According to the literature, Neb inhibits β1-AR and activates β3-AR. Neb also inhibits mTORC1 and suppresses miR-208a (this study and ref#14). Since inhibition of β3-AR or AMPK did not reverse Nebinduced suppression of Ang II-induced increase in miR-208a expression, we posit that Nebmediated β3-AR activation is not involved in Neb-mediated suppression of Ang II-induced miR-208a expression. However, Neb suppressed bioavailable AT1R. Since AT1R is needed for Ang II-induced mTORC1 activation and miR-208a expression, this suggests that the Neb-mediated suppression of Ang II-induced miR-208a expression arises from downregulation of the AT1R. Finally, suppression of miR-208a by Rap mediated inhibition of mTOR leads to up-regulation of MED-13 (also known as THRAP1) which, in turn, can improve energy homeostasis and reduce obesity.
